APPARATUS AND METHOD FOR COMBINED CARDIAC FUNCTION MANAGEMENT AND RENAL THERAPIES

• US 20120303079A1
• Filed: 05/22/2012
• Published: 11/29/2012
• Est. Priority Date: 05/23/2011
• Status: Abandoned Application

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Mahajan, Deepa, Wariar, Ramesh, Shome, Shibaji
• Application Number:
  US13/477,148
• Publication Number:
  US 20120303079A1
• Time in Patent Office: Days
• US Class Current: 607/14
• CPC Class Codes: A61N 1/36557 controlled by chemical substances in blood
• CPC Class Codes: A61N 1/36564 controlled by blood pressure
• CPC Class Codes: A61N 1/36571 controlled by blood flow rate, e.g. blood velocity or cardiac output
• CPC Class Codes: A61N 1/37288 Communication to several implantable medical devices within one patient

Abstract

A system can coordinate operation of a cardiac function management (CFM) device and a renal device, such as during a vulnerable period in which a patient has an increased risk of tachyarrhythmia.

Claims

1. An apparatus, comprising:

an ambulatory cardiac function management device comprising;

a data input configured to receive information about or from an external renal monitoring or therapy device;

a control circuit, comprising first and second operating modes, the first operating mode controlling operation of the implantable cardiac function management device in the absence of triggering information about or from the renal monitoring or therapy device, and the second operating mode controlling operation of the implantable cardiac function management device in response to receiving triggering information about or from the renal monitoring or therapy device; and

wherein the second operating mode includes an exit condition, returning control of operation of the implantable cardiac function management device to the first operating mode, when a vulnerable period, including a time period corresponding to an increased risk of tachyarrhythmia or intradialytic hypotension, has elapsed.

2. The apparatus of claim 1, wherein the control circuit is configured to adjust or direct therapy, provided by the cardiac function management device, in response to the triggering information received from the renal monitoring or therapy device.

3. The apparatus of claim 2, wherein the control circuit is configured to adjust or direct an anti-tachyarrhythmia therapy, provided by the cardiac function management device, in response to the triggering information received from the renal monitoring or therapy device.

4. The apparatus of claim 1, wherein the control circuit is configured to adjust or direct a physiological sensor of the cardiac function management device in response to the triggering information received from the renal monitoring or therapy device.

5. The apparatus of claim 4, wherein the control circuit is configured to qualify or flag data from the physiological sensor of the cardiac function management device using the triggering information received from the renal monitoring or therapy device.

6. The apparatus of claim 1, wherein the control circuit is configured to adjust determination of a thoracic fluid accumulation status or a congestive heart failure status in response to the triggering information received from the renal monitoring or therapy device.

7. The apparatus of claim 1, wherein the operating mode of the cardiac function management device is adjusted in response to the triggering information received from the renal monitoring or therapy device, wherein the triggering information indicates at least one of:

(1) initiation of renal therapy;

(2) adjustment of ongoing renal therapy;

(3) cessation of renal therapy;

or (4) a physiologic condition indicated by the renal monitoring or therapy device.

8. The apparatus of claim 1, wherein the second operating mode of the cardiac function management device includes adjusting, with respect to the first operating mode, at least one of pacing rate, electrostimulation energy, electrostimulation electrode configuration, interelectrode electrostimulation delay, His-bundle pacing, or anti-tachyarrhythmia therapy.

9. An apparatus, comprising:

a renal monitoring or therapy device comprising;

a tachyarrhythmia vulnerability detection circuit, configured to monitor a patient physiological or device operational renal parameter that varies during or in response to renal therapy, and to determine whether the renal parameter indicates a vulnerable period corresponding to an increased risk of a present or future tachyarrhythmia episode; and

a communication circuit, configured to communicate directly or indirectly to an ambulatory cardiac function management device to provide a tachyarrhythmia vulnerability mode trigger configured to alter operation of the cardiac function management device in response to the trigger.

10. The apparatus of claim 9, wherein renal monitoring or therapy device includes a control circuit that is configured to direct therapy provided by the renal monitoring or therapy device in response to information received from the cardiac function management device about at least one of a tachyarrhythmia vulnerability of the subject, a fluid accumulation status of the subject, or a congestive heart failure status of the subject.

11. The apparatus of claim 9, wherein the renal monitoring or therapy device is configured to adjust or direct an anti-tachyarrhythmia therapy, provided by the cardiac function management device.

12. The apparatus of claim 9, wherein the renal monitoring or therapy device is configured to adjust determination of a thoracic fluid accumulation status or a congestive heart failure status by the cardiac function management device.

13. The apparatus of claim 9, wherein the renal monitoring or therapy device is configured to adjust an operating mode of the cardiac function management device using information about at least one of:

(1) initiation of renal therapy;

(2) adjustment of ongoing renal therapy;

(3) cessation of renal therapy;

or (4) a physiologic condition indicated by the renal monitoring or therapy device.

14. The apparatus of claim 9, wherein the control circuit is configured to adjust or direct the renal monitoring therapy, in response to the information received from the cardiac function management device, by providing a control signal to modify at least one of the following:

dialysis, blood flow rate, dialysate flow rate, ultrafiltration, dialysate composition, or infusion.

15. An apparatus, comprising:

an implantable cardiac function management device comprising;

a tachyarrhythmia detection or prediction circuit, configured to detect the presence of an existing or a predicted future tachyarrhythmia episode; and

a communication circuit, configured to communicate directly or indirectly to an external renal monitoring or therapy device triggering information that is configured to alter operation of the renal monitoring or therapy in response to the triggering information.

16. The apparatus of claim 15, wherein the communication circuit is configured to communicate directly or indirectly to an external renal monitoring or therapy device triggering information indicating a tachyarrhythmia vulnerability including at least one of:

heart rate, heart rate variability, premature ventricular contraction information, long-short contraction sequence information, prolonged QT interval information, or blood analyte information.

17. The apparatus of claim 16, wherein the communication circuit is configured to communicate directly or indirectly, to an external renal monitoring or therapy device, triggering information that is configured to adjust or direct the renal monitoring or therapy, including at least one of the following:

ultrafiltration, infusion, or dialysis.

18. A method comprising:

detecting a tachyarrhythmia vulnerable period using at least one of an ambulatory cardiac function management device or an renal therapy device; and

in response to the detecting, communicating triggering information to the other of the cardiac function management device or the renal therapy device to trigger such other of the cardiac function management device or the renal therapy device to switch from a first operating mode to a second operating mode, wherein the second operating mode is configured for use during the tachyarrhythmia vulnerable period.

19. The method of claim 18, comprising switching the cardiac function management device from the first operating mode to the second operating mode, and wherein the second operating mode of the cardiac function management device includes adjusting, with respect to the first operating mode, at least one of pacing rate, electrostimulation energy, electrostimulation electrode configuration, interelectrode electrostimulation delay, His-bundle pacing, or anti-tachyarrhythmia therapy.

20. The method of claim 19, wherein the renal monitoring or therapy device is configured to adjust an operating mode of the cardiac function management device using information about at least one of:

(1) initiation of renal therapy;

(2) adjustment of ongoing renal therapy;

(3) cessation of renal therapy;

or (4) a physiologic condition indicated by the renal monitoring or therapy device.